lansoprazole / Generic mfg. - LARVOL DELTA

Effects of crocetin, a constituent of saffron, on indomethacin-induced gastric ulcer and related anxiety-like behavior in rats. (PubMed, Phytomedicine) - "CRT and LAP caused protective effects against IND-induced gastric ulcer and by antioxidative, anti-inflammatory, anti-apoptotic and PGE2-increasing activities. Anxiolytic effects of CRT and LAP were also observed."

Journal • Preclinical • Mood Disorders • Oncology • Peptic Ulcer • Psychiatry • BDNF • CASP3 • IL1B • TNFA

Lansoprazole Improves Long-Term Neurological Function via Alleviating Intestinal Injury in a Mouse Model of Intracerebral Hemorrhage. (PubMed, J Vis Exp) - "While lansoprazole administration did not lead to improved performance in the Garcia, forelimb placing, and rotarod tests (short-term neurological function), it significantly enhanced learning and memory (long-term neurological function). These findings indicated that lansoprazole treatment was associated with improved long-term neurological outcomes and reduced intestinal injury in ICH mice."

Journal • Preclinical • Cerebral Hemorrhage • Gastrointestinal Disorder • Hematological Disorders • Inflammation • IL1B

Vonoprazan-tetracycline dual regimen as rescue therapy for Helicobacter pylori infection: randomized controlled trial. (PubMed, Gastroenterology) - P=N/A | "Fourteen-day vonoprazan-tetracycline dual therapy is an effective and well-tolerated rescue regimen for Helicobacter pylori infection. This simplified regimen achieved eradication rates non-inferior to BQT while substantially reducing adverse events and improving adherence. (chictr.org.cn, ChiCTR2400080705)."

Journal • Infectious Disease

The Efficacy of Keveprazan, Vonoprazan, and Lansoprazole for the Treatment of Gastroesophageal Reflux Disease: A Network Meta-Analysis. (PubMed, Curr Top Med Chem) - "In patients with EO, both 20 mg VPZ and 30 mg LPZ demonstrated relatively lower efficacy in subtypes C/D compared to subtypes A/B. Furthermore, 8-week interventions with either 20 mg VPZ or 30 mg LPZ provided significantly greater clinical benefit compared to 2-week regimens. Notably, 40 mg VPZ was associated with the lowest incidence of TEAEs, as well as TEAEs occurring in at least 2% of patients (TEAEs ≥2%)."

Clinical • Journal • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • GAST

Proton pump inhibitors accelerate vascular calcification via COX-2-mediated mitophagy inhibition in chronic kidney disease. (PubMed, Eur J Pharmacol) - "Enhancement of mitophagy by rapamycin effectively mitigated omeprazole-induced VC...Esomeprazole and lansoprazole recapitulated these pro-calcific effects, indicating a class effect. Collectively, PPIs promote VC in CKD by upregulating COX-2, which directly inhibits PINK1/Parkin-related mitophagy. This study provides a novel COX-2-mitophagy axis in PPI-accelerated vascular injury, highlighting a potential therapeutic target for high-risk patients."

Journal • Cardiovascular • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease • PTGS2

Proton Pump Inhibitor-Induced Fundic Gland Polyps With Massive Bleeding Regressed on Alternative Histamine 2 Receptor Antagonist Therapy. (PubMed, DEN Open) - "A 46-year-old man with antiphospholipid syndrome had been receiving warfarin and lansoprazole for 4 years. This case demonstrates that PPI-induced FGPs can result in massive bleeding, particularly in patients receiving anticoagulant therapy. Furthermore, FGP regression following the switch to H2RA suggests that H2RA therapy may be an alternative treatment when discontinuation of PPI therapy is not feasible."

Journal • Gastroenterology • Genetic Disorders • Hematological Disorders

Drug-Induced Liver Injury with Eosinophilia: A Case-Control Study Using Electronic Medical Records. (PubMed, Biol Pharm Bull) - "Sulbactam/cefoperazone showed the strongest association with DILI-Eos (adjusted odds ratio (OR) 14.51; 95% confidence interval (CI) 10.09-20.85), followed by meropenem (OR 5.68; 95% CI 4.10-7.82) and tazobactam/piperacillin (OR 3.55; 95% CI 2.63-4.75). Several commonly used drugs, such as mosapride, lansoprazole, furosemide, and ambroxol, were also significantly associated with increased risk...Notably, substantial variability in risk was observed even within the same drug classes, such as β-lactam antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), underscoring the importance of drug-specific evaluation. Further studies are needed to clarify the causality and mechanisms underlying eosinophilic responses in DILI."

Journal • Eosinophilia • Hepatology • Immunology • Liver Failure

Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers. (PubMed, Gut Liver) - P3 | "An 8-week therapy involving zastaprazan 20 mg demonstrated noninferiority to lansoprazole 30 mg in the cumulative rate of healing of gastric ulcers at 8 weeks, and the two demonstrated similar safety profiles. (ClinicalTrials.gov identifier NCT05448001)."

Clinical • Journal • P3 data • Gastroenterology • Gastrointestinal Disorder • Peptic Ulcer • GAST

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. (PubMed, Helicobacter) - P2 | "Tegoprazan-based triple therapies, at 50- and 100-mg doses, were non-inferior to lansoprazole-based therapy and were well tolerated. Our findings indicated that tegoprazan-based triple therapy is a viable first-line option for H. pylori eradication."

Clinical • Journal • P3 data • Infectious Disease

Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial (clinicaltrials.gov) - P2/3 | N=670 | Not yet recruiting | Sponsor: Stanford University

Biomarker • New P2/3 trial

Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids (clinicaltrials.gov) - P4 | N=42 | Completed | Sponsor: Yonsei University | Not yet recruiting ➔ Completed | N=70 ➔ 42 | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study. (PubMed, J Korean Med Sci) - "In this national longitudinal study, PCAB users had a lower likelihood of developing depression than PPI users. Additional studies on the biological mechanism for the risk of depression and gastric acid suppressants are needed."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy and Safety of Levofloxacin- Versus Moxifloxacin-Based Nitazoxanide Quadruple Therapy as Second-Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial. (PubMed, Helicobacter) - "Both nitazoxanide-based quinolone quadruple regimens demonstrated modest but clinically relevant efficacy as second-line therapy. Moxifloxacin showed superior performance in patients with prior levofloxacin exposure. These findings support the use of moxifloxacin-based rescue therapy in settings with high resistance and limited access to bismuth-containing regimens."

Clinical • Journal • Infectious Disease

Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication. (PubMed, PLoS Med) - "Apparent harmful associations between PPI use and upper GI cancer were concentrated in the months immediately preceding diagnosis and disappeared after adjusting for diagnostic context and excluding the final year before diagnosis. In these adjusted analyses, we found no evidence of increased odds with long-term PPI use, and remote use (>3 years before diagnosis) was associated with reduced cancer odds for omeprazole and lansoprazole. These findings underscore the importance of investigating new-onset upper GI symptoms rather than attributing malignancy risk to acid-suppressive therapy."

Journal • Esophageal Cancer • Gastric Cancer • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Cancer • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

A Randomized, Phase 3 Multicenter Clinical Trial to Confirm the Clinical Efficacy and Evaluate the Safety of Linaprazan Glurate Compared to Lansoprazole in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - P3 | N=1050 | Not yet recruiting | Sponsor: Cinclus Pharma Holding AB

New P3 trial • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Drug-related hepatotoxicity risk in elderly patients with atrial fibrillation: insights from the nationwide Italian START registry. (PubMed, Sci Rep) - "The most commonly prescribed LiverTox A drugs were statins, amiodarone, and allopurinol, both in the overall population and within subgroups stratified by major cardiovascular conditions. In multivariable logistic regression, among LiverTox A drugs, amiodarone (OR 1.61, 95%CI 1.29-2.00) and methimazole (OR 1.83, 95%CI 1.04-3.03) were associated with elevated LFTs. Among frequently prescribed drugs, warfarin, furosemide, ramipril, lansoprazole, and canrenone were also associated with increased LFTs. Direct oral anticoagulants, compared to warfarin, showed a lower risk of increased LFTs after adjustment for confounders. In conclusion, many AF patients are treated with drugs at high risk of hepatotoxicity."

Journal • Atrial Fibrillation • Cardiovascular • Hepatology • Liver Failure • Obesity

Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach. (PubMed, Pharmaceutics) - " We constructed a physiologically based pharmacokinetic (PBPK) model that incorporates six drugs, including omeprazole, lansoprazole, midazolam, ondansetron, verapamil, and alfentanil, which are metabolized primarily by CYP2C19 or CYP3A4. The clinical dosing regimens of the CYP2C19 substrate omeprazole and the CYP3A4 substrate ondansetron were optimized for use in cirrhotic patients. The developed PBPK model successfully predicted the pharmacokinetics of CYP2C19 and CYP3A4 substrates in both healthy individuals and cirrhotic patients and can be effectively used for dose optimization in cirrhotic populations."

Journal • PK/PD data • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • CYP2C19 • CYP3A4

Dose and duration shape the efficacy of vonoprazan versus lansoprazole for erosive esophagitis: insights from meta-regression. (PubMed, Therap Adv Gastroenterol) - "Its benefits are dose- and duration-dependent, supporting vonoprazan as a first-line option for EE, particularly in severe or PPI-refractory cases. This study was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY; INPLASY202590075; DOI: 10.37766/inplasy2025.9.0075)."

Journal • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • GAST

Drug Development. (PubMed, Alzheimers Dement) - "In summary, we demonstrated a single-cell digital twin framework for cell type-specific target identification and drug repurposing in AD and other AD-related dementia if broadly applied."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • ABCA1

Efficacy, safety and cost-effectiveness of potassium-competitive acid blockers versus proton pump inhibitors in gastroesophageal reflux disease. (PubMed, Scand J Gastroenterol) - "Subgroup analysis showed P-CABs had a significant advantage over lansoprazole (P < 0.001, RR = 0.50), but not over esomeprazole (P = 0.93). PPIs are more cost-effective in specific contexts. Due to the limited follow-up duration in the included studies, the conclusions are applicable only to short-term symptom control."

HEOR • Journal • Gastroenterology • Gastroesophageal Reflux Disease

TIPAL: Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole (clinicaltrials.gov) - P3 | N=298 | Recruiting | Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Aug 2024 ➔ Feb 2026

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Comparing the Interactions of Trichomonas vaginalis/gallinae Legumain-Like Cysteine Protease 1 (LEGU-1) and Human Legumain (LGMN) Protein Sequences with Proton Pump Inhibitor Drugs (Lansoprazole, Omeprazole, and Esomeprazole) by Bioinformatics Analyses. (PubMed, Acta Parasitol) - "Conclusion Beyond our promising bioinformatics results, this study can guide further research on the development of alternative therapeutic methods against trichomoniasis and concomitant conditions."

Clinical • Journal • Infectious Disease • Oncology • Urology • LGMN

Comparative Efficacy of Potassium-Competitive Acid Blockers (P-CABs) Versus Proton Pump Inhibitors (PPIs) in the Management of Erosive Esophagitis: A Systematic Review. (PubMed, Cureus) - "Across studies, vonoprazan consistently demonstrated noninferiority and, in many cases, superiority to lansoprazole, with higher healing rates and lower recurrence, particularly in patients with severe disease (Los Angeles Grade C/D). While most evidence originates from Asian populations and some studies had open-label designs, evidence suggests vonoprazan as a potent alternative to PPIs for both induction and maintenance of EE. These results provide clinically meaningful insights for optimizing acid-suppressive therapy and highlight the need for broader, global trials."

Journal • Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Oncology

A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile (clinicaltrials.gov) - P=N/A | N=500 | Recruiting | Sponsor: Miguel O'Ryan Gallardo | Trial completion date: Mar 2027 ➔ Aug 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Infectious Disease

Evaluation of the Safety and Efficacy of K-CAB (Tegoprazan) as Symptomatic Maintenance Therapy in Patients With NERD: A Multicenter, Randomized Double-Blinded Controlled Trial. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "Both treatments were well tolerated, with no serious adverse events reported. These findings suggest that alternate-day tegoprazan offers comparable efficacy and safety to daily lansoprazole therapy and may serve as a more flexible and patient-friendly maintenance option for NERD."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease